Drug Type TCR-T Cell therapy |
Synonyms TSC 200 (HLA-C*07:02), TSC200 (HLA-C*07:02) |
Target |
Action inhibitors |
Mechanism E7 inhibitors(HPV E7 inhibitors), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Solid tumor | Preclinical | United States | - | |
| Anus Neoplasms | Discovery | United States | 01 Dec 2024 | |
| Head and Neck Neoplasms | Discovery | United States | 01 Dec 2024 | |
| Uterine Cervical Cancer | Discovery | United States | 01 Dec 2024 |





